"The
Report Critical Care Market to 2019 - Growth from Factor
Concentrates, New Indications and Increasing Demand for Albumin in
Asia-Pacific provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
GBI
Research, the leading business intelligence provider, has released
its latest research, “Critical Care Market to 2019 - Growth from
Factor Concentrates, New Indications and Increasing Demand for
Albumin in Asia-Pacific”. The report provides in-depth analysis of
the drivers and barriers that affect the global critical care market.
The report has been compiled using data and information sourced from
proprietary databases, primary and secondary research, and in-house
analysis carried out by GBI Research’s team of industry experts.
The
report analyzes the markets for factor XIII concentrates, fibrinogen
concentrates, albumins, antithrombins and prothrombin complex
concentrates in the US, the top five countries of Europe (the UK,
Germany, France, Italy and Spain), and Japan. The report does also
provide an overview on Asia-Pacific countries, including China, India
and Australia. The report provides an overview of major marketed
products in critical care market along with treatment usage patterns,
average annual cost of therapy and market forecast to 2019 for key
geographical markets, as well as for leading therapeutic segments.
View Report At
http://www.marketresearchreports.biz/analysis/167891
The
report also provides information on the Research and Development
(R&D) product pipeline and explores the competitive landscape,
including the provision of profiles for major players in the critical
care market. Finally, the report includes analysis of Mergers and
Acquisitions (M&A) activity in the critical care market. GBI
Research’s analysis indicates that the global critical care market
is still an untapped market, with a small number of players
accounting for a major proportion of the overall market. The market
grew at a very slow growth rate between 2006 and 2012, possibly due
to the lac of availability of many of the products in certain
markets, especially in the US.
GBI
Research estimates that the overall critical care therapeutics market
was worth $2.3 billion in 2012, having grown in size at a CAGR of 11%
from $1.2 billion in 2006. The market is expected to grow at a CAGR
of 5% to reach $3.2 billion in 2019. The double-digit market growth
registered between 2006 and 2012 can be attributed primarily to the
increased demand for and cost of albumin, as well as the approval and
launch of new products. The growth of the overall critical care
market during the forecast period is expected to be largely due to an
increasing preference in the market for factor concentrates such as
Riastap, Corifact, rFXIII (which has been launched in the EU and is
expected to be launched in the US later this year), the expanded
indication for Antithrombin (AT) III and factor concentrates, and
rising demand for albumin from countries in the Asia-Pacific region.
Stagnant innovations, a low prevalence rate and the consequent
limited availability of patients are some of the factors impeding the
growth of the critical care market.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/167891
Scope
- Data and analysis regarding the critical care market in leading geographical locations – the US, the UK, Germany, France, Italy, Spain, and Japan and Asia-Pacific countries, including India, China and Australia.
- Annualized market data for the critical care market, including the individual markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2006 to 2012, with forecasts provided up to 2019.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume, and treatment usage patterns, such as disease population, diagnosis population and prescription population.
- Key drivers and restraints that have had a major impact upon the market.
- An overview of the competitive landscape of the global critical care market, including benchmarking for leading companies. Some of the key companies studied in this report are CSL, Octapharma, Baxter, Grifols, and LFB.
- Key M&A activities that took place in 2010 and 2011 in the critical care market.
Reasons to buy
- Align company product portfolios to markets with high growth potential.
- Build effective strategies to launch pipeline products, by identifying potential geographical markets.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms capable of producing first-in-class molecules which are safer and more efficacious
Read
our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
Table
of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
3 Critical Care Market to 2019 –
Global Overview
4 Critical Care Market to 2019 –
Geographical Landscape
4.1 Introduction
4.2 The US – Critical Care
Market
4.2.1 Revenue
4.3 Top Five European Countries –
Critical Care Market
4.3.1 Revenue
4.4 Japan – Critical Care Market
4.4.1 Revenue
5 Critical Care Market to 2019 –
Albumin Market
5.1 Introduction
5.2 Marketed Albumin Products
5.2.1 Buminate
5.2.2 Zenalb
5.2.3 Human Albumin Biotest
5.2.4 AlbuRx
5.2.5 Albuminar
5.2.6 Albutein
5.2.7 Albuked
5.2.8 Vialebex
5.2.9 Albunorm
5.2.10 AlbuRAAS
5.3 Revenue
5.4 Cost of Therapy
5.5 China
5.5.1 Introduction
5.5.2 Strict Regulatory Reforms
Leading to Tighter Supply
5.5.3 Fragmented Market Dominated
by Overseas Players
5.5.4 Price of Albumin Likely to
Remain High
5.5.5 Conclusion
5.6 India
5.7 Australia
5.7.1 Introduction
5.7.2 Rising Albumin Demand
5.7.3 Australian Albumin Market
5.8 Market Drivers and Barriers
5.8.1 Market Drivers
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment